Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more
Merck & Co. Inc. (NYSE:MRK) hired Matthew Walsh as CFO and Rachel Stahler as chief information officer of its planned spinout Organon & Co. Walsh was EVP and CFO of Allergan plc, which was acquired by AbbVie Inc. (NYSE:ABBV) in May, and Stahler was CIO. Merck plans to complete the spin out of its women’s health business, legacy brands and biosimilars into Organon in 1H21 (see “How Merck Envisions Innovation and Growth After a Spinout”).
The board of Chinese mobile health and wellness company Ping An Healthcare and Technology Co. Ltd. (HKEX:1833) will remove Chairman and CEO Wang Tao after he “did not perform his management responsibility up to the expectation of the Board,” according to a financial filing. The board appointed Fang Weihao as acting chairman and CEO. He is chairman and CEO of Ping An International Finance Leasing Co. Ltd. and co-chairman and CEO of Ping An Medical and Healthcare Management Co. Ltd...